Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)

Exclusion Criteria

• •1. Any current tumor diseases, including squamous cell carcinoma and basal cell carcinoma;
• •2. Any known allergies to components of the IP or premedication;
• •3. Patient/legal representative anticipated to be unwilling or unable to comply with the requirements of the protocol;
• •4. Pregnant or lactating women;
• •5. Current or previous (within 30 days of screening) treatment with another IP, or participation and/or under follow-up in another interventional clinical trial;
• •6. Previous participation in this clinical trial (except for screening failures);
• •7. Clinically significant or unstable concurrent disease or other clinical contraindications like an uncontrolled or poorly controlled mental health condition of the subject and/or his/her legal representative that could impact on patient's safety or interfere with study compliance such as inability to attend scheduled study visits; Confidential
• •8. Employees of the sponsor, or employees or relatives of the investigator.